FERRERO, Dario
Dettaglio
FERRERO, Dario
BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE
Pubblicazioni
Risultati 1 - 20 di 138 (tempo di esecuzione: 0.001 secondi).
Titolo | Data di pubblicazione | Autore(i) | |
---|---|---|---|
1 | A novel human lymphokine that inhibits haematopoietic progenitor cell proliferation. | 1984 | TRUCCO M ;ROVERA G ;FERRERO D |
2 | A POST-REMISSION MAINTENANCE TREATMENT WITH LOW-DOSE CHEMOTHERAPY + RETINOIDS AND DIHYDROXYLATED VITAMIN D3 MAY IMPROVE THE SURVIVAL OF POOR-PROGNOSIS AML/MDS PATIENTS | 2014 | Dario Ferrero; Elena Crisà; Filippo Marmont; Ernesta Audisio; Chiara Frairia; Valentina Giai; Tiziana Gatti; Moreno Festuccia; Benedetto Bruno; Ludovica Riera; Roberto Passera; Mario Boccadoro |
3 | A retrospective real-life analysis of chronic myeloid leukemia patients in suboptimal response to imatinib: three centres experience. | 2012 | Ferrero D; Crisà E; Rege-Cambrin G; Fava C; Cerrano M; Pirillo F; Nicolosi M; Boccadoro M; Saglio G; Vitolo U; Pregno P. |
4 | A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs | 2010 | Crisà E; Venturino E; Passera R; Prina M; Schinco P; Borchiellini A; Giai V; Ciocca Vasino MA; Bazzan M; Vaccarino A; Boccadoro M; Ferrero D |
5 | A single step density gradient separation for large scale enrichment of mobilized peripheral blood progenitor cells collected for autotransplantation. | 1998 | FERRERO D ;TARELLA C ;CHERASCO C ;BONDESAN P ;OMEDÈ P ;RAVAGLIA R ;CARACCIOLO D ;CASTELLINO C ;PILERI A |
6 | A suppressor lymphokine produced by human T leukemia cell lines. Partial characterization and spectrum of activity against normal and malignant hemopoietic cells. | 1986 | SANTOLI D ;TWEARDY DJ ;FERRERO D ;KREIDER BL ;ROVERA G |
7 | A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. | 2001 | M. LADETTO; SAMETTI S; DONOVAN JW; FERRERO D; ASTOLFI M; MITTERER M; RICCA I; DRANDI D; CORRADINI P; COSER P; PILERI A; GRIBBEN JG; TARELLA C. |
8 | Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology. | 1989 | PILERI A ;FERRERO D ;MASSAIA M ;DIANZANI U ;BOCCADORO M |
9 | Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. | 2014 | Breccia M; Luciano L; Latagliata R; Castagnetti F; Ferrero D; Cavazzini F; Trawinska MM; Annunziata M; Stagno F; Tiribelli M; Binotto G; Crisà E; Musto P; Gozzini A; Cavalli L; Montefusco E; Iurlo A; Russo S; Cedrone M; Rossi AR; Pregno P; Endri M; Spadea A; Molica M; Giglio G; Celesti F; Sorà F; Storti S; D'Addosio A; Cambrin GR; Isidori A; Sica S; Abruzzese E; Speccha G; Rosti G; Alimena G. |
10 | Anemia in the Elderly: not Always what it Seems. | 2016 | Cerrano, Marco; Crisà, Elena; Giai, Valentina; Boccadoro, Mario; Ferrero, Dario |
11 | Angiocentric lymphoma: a case report. | 1990 | DARBESIO A ;FERRERO D |
12 | Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders. | 1986 | Ferrero D; Tarella C; Pregno P; Pileri A; Gallo E. |
13 | Antigenically distinct subpopulations of myeloid progenitor cells (CFU-GM) in human peripheral blood and marrow. | 1983 | D. FERRERO; BROXMEYER HE; PAGLIARDI GL; VENUTA S; LANGE B; PESSANO S; ROVERA G |
14 | Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. | 1987 | Ferrero D; De Fabritiis P; Amadori S; De Felice L; Gallo E; Meloni G; Pregno P; Pulsoni A; Simone F; Tarella C; Pileri A; Rovera G; Mandelli F |
15 | Azacitidine for the treatment of patients with acute myeloid leukemia : Report of 82 patients enrolled in an Italian compassionate program | 2012 | Maurillo L; Venditti A; Spagnoli A; Gaidano G; Ferrero D; Oliva E; Lunghi M; D'Arco AM; Levis A; Pastore D; Di Renzo N; Santagostino A; Pavone V; Buccisano F; Musto P. |
16 | The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. | 2012 | Fausto Castagnetti; Gabriele Gugliotta; Massimo Breccia; Giorgina Specchia; Elisabetta Abruzzese; Luciano Levato; Francesco Cavazzini; Alessandra Iurlo; Fabio Stagno; Dario Ferrero; Ferdinando Porretto; Bruno Martino; Serena Rupoli; Tamara Intermesoli; Carmen Fava; Francesca Palandri; Claudia Venturi; Simona Soverini; Nicoletta Testoni; Giuliana Alimena; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli; Michele Baccarani; and Gianantonio Rosti. |
17 | Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia | 2019 | Dragani M.; Rege-Cambrin G.; Ferrero D.; Abruzzese E.; Pregno P.; Elena C.; Cedrone M.; Santoro M.; Andreani G.; Saglio G.; Fava C. |
18 | c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells. | 1998 | M. BRIZZI; A. ROSSO; P. DENTELLI; D. FERRERO; L. LANFRANCONE ; L. PEGORARO. |
19 | Can pegylated interferon improve the outcome of polycythemia vera patients? | 2017 | Crisa E.; Cerrano M.; Beggiato E.; Benevolo G.; Lanzarone G.; Manzini P.M.; Borchiellini A.; Riera L.; Boccadoro M.; Ferrero D. |
20 | Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? | 2013 | Santini V; Schemenau J; Levis A; Balleari E; Sapena R; Adès L; Guerci A; Beyne-Rauzy O; Gourin MP; Cheze S; Stamatoullas A; Sanna A; Gioia D; Cametti G; Ferrero D; Raffoux E; Rose C; Poloni A; Prebet T; Legros L; Natarajan-Amé S; Fenaux P; Germing U; Dreyfus F; Park S. |